Ali Raza Khaki, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khaki’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A133860 · Current
Licensed to practise in California · since 2014 · expires 2026-11-30 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MD.MD.60868159Physician And Surgeon License · since 2018 · expires 2027-11-23ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$132,347
Medicare paid this office $132,347 for 284 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 111 | $42,887 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $20,651 | $106 |
| Long return visit (40+ min) | 66 | $19,303 | $122 |
| Return visit (30+ min) | 85 | $17,344 | $115 |
| New patient visit (60+ min) | 33 | $6,379 | $193 |
See all 11 services
| Long return visit (40+ min) | 111 | $42,887 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $20,651 | $106 |
| Long return visit (40+ min) | 66 | $19,303 | $122 |
| Return visit (30+ min) | 85 | $17,344 | $115 |
| New patient visit (60+ min) | 33 | $6,379 | $193 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,378 | $156 |
| Hospital discharge day management, more than 30 minutes | 38 | $3,987 | $105 |
| New patient visit (60+ min) | 24 | $3,690 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 115 | $3,445 | $15 |
| Return visit (30+ min) | 21 | $2,110 | $81 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 59 | $1,513 | $15 |
Procedures Medicare counted
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
284 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 11% · Women 23% · Also on Medicaid 24% · Health risk score 2.36. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 75% · Chronic kidney disease 38% · Diabetes 36% · Coronary heart disease 31% · Atrial fibrillation 23% · Depression 21% · Heart failure 19% · Dementia 14% · Stroke 13% · COPD 12%.
The office billed $614,575, Medicare allowed $171,610 and paid $132,347; for 1,303 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 284 | 1,303 | 75 | 2.36 | $614,575 | $132,347 |
| 2023 | 284 | 918 | 75 | 2.25 | $501,682 | $106,918 |
| 2022 | 217 | 756 | 75 | 2.46 | $436,929 | $88,580 |
| 2021 | 144 | 585 | 73 | 2.29 | $298,919 | $66,256 |
| 2020 | 14 | 28 | 75 | 2.18 | $7,462 | $2,463 |
| 2017 | 139 | 506 | 75 | 3.40 | $190,540 | $48,975 |
| 2016 | 58 | 233 | 75 | 2.67 | $91,775 | $23,924 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 121 | $37,913 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $25,560 | $110 |
| New patient visit (60+ min) | 84 | $13,459 | $160 |
| Return visit (30+ min) | 61 | $9,236 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $7,677 | $160 |
| Hospital discharge day management, more than 30 minutes | 51 | $5,891 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,918 | $73 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,215 | $76 |
2022: 8 services
| Long return visit (40+ min) | 80 | $32,739 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $18,796 | $94 |
| New patient visit (60+ min) | 75 | $12,305 | $164 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $9,340 | $180 |
| Hospital discharge day management, more than 30 minutes | 42 | $4,417 | $98 |
| Return visit (30+ min) | 31 | $3,980 | $90 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,542 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,111 | $65 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $21,697 | $96 |
| Long return visit (40+ min) | 31 | $14,605 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $9,101 | $186 |
| New patient visit (60+ min) | 37 | $6,437 | $174 |
| Hospital discharge day management, more than 30 minutes | 49 | $5,331 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,069 | $67 |
| Return visit (30+ min) | 14 | $1,402 | $93 |
2017: 7 services
| Critical care, first 30-74 minutes | 32 | $13,078 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $10,985 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $7,462 | $93 |
| Hospital discharge day management, more than 30 minutes | 47 | $4,704 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,836 | $174 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 15 | $2,404 | $63 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 12 | $2,093 | $84 |
2016: 6 services
| Critical care, first 30-74 minutes | 11 | $7,275 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $3,299 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $3,167 | $90 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 15 | $2,354 | $84 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 11 | $1,851 | $64 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,821 | $96 |
Medicaid work
$7,828 in 2024
Medicaid paid $7,828 for 154 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 130 | $5,914 |
| Long return visit (40+ min) | 24 | $1,914 |
| 2024 | 154 | 2 | 15 | $7,828 |
| 2023 | 183 | 3 | 18 | $9,056 |
| 2022 | 136 | 3 | 15 | $5,582 |
| 2021 | 129 | 2 | 15 | $4,305 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 111 | $5,150 |
| Long return visit (40+ min) | 58 | $2,902 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $1,004 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 108 | $4,075 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $816 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 16 | $691 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 117 | $3,121 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $1,184 |
Drugs they prescribed that Part D paid
$768,452
Pharmacies billed $768,452 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (16 of 438) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
363 generic and fewer than 11 brand-name prescriptions · $768,452 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 27 | $339,397 | $12,570 |
| Abiraterone Acetate | 87 | $48,665 | $559 |
| Eliquis | 13 | $7,184 | $553 |
| Prednisone | 80 | $342 | $4 |
| Prochlorperazine Maleate | 23 | $200 | $9 |
See all 8 drugs
| Xtandi | 27 | $339,397 | $12,570 |
| Abiraterone Acetate | 87 | $48,665 | $559 |
| Eliquis | 13 | $7,184 | $553 |
| Prednisone | 80 | $342 | $4 |
| Prochlorperazine Maleate | 23 | $200 | $9 |
| Ondansetron | 30 | $149 | $5 |
| Dexamethasone | 16 | $130 | $8 |
| Tamsulosin | 13 | $86 | $7 |
Year by year
| 2024 | 438 | 93 | 4% (16) | None | $768,452 |
| 2023 | 345 | 73 | 5% (17) | 16% | $671,692 |
| 2022 | 302 | 49 | None | 11% | $403,402 |
| 2021 | 155 | 32 | 7% (11) | None | $134,857 |
| 2020 | 41 | None | None | 56% | $141,134 |
| 2019 | 75 | 15 | None | 31% | $148,245 |
| 2018 | 50 | 18 | None | None | $21,249 |
| 2017 | 126 | 59 | None | None | $8,423 |
| 2016 | 105 | 39 | None | None | $5,572 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Nubeqa | 19 | $271,626 | $14,296 |
| Abiraterone Acetate | 77 | $177,957 | $2,311 |
| Xtandi | 11 | $141,805 | $12,891 |
| Orgovyx | 14 | $38,597 | $2,757 |
| Prednisone | 92 | $756 | $8 |
| Tamsulosin | 13 | $425 | $33 |
| Prochlorperazine Maleate | 17 | $170 | $10 |
| Ondansetron | 16 | $124 | $8 |
| Dexamethasone | 12 | $102 | $9 |
2022: 7 drugs
| Abiraterone Acetate | 62 | $102,433 | $1,652 |
| Orgovyx | 11 | $28,541 | $2,595 |
| Bicalutamide | 15 | $697 | $46 |
| Prednisone | 81 | $529 | $7 |
| Tamsulosin | 19 | $294 | $15 |
| Ondansetron | 13 | $182 | $14 |
| Dexamethasone | 18 | $158 | $9 |
2021: 3 drugs
| Abiraterone Acetate | 26 | $62,788 | $2,415 |
| Bicalutamide | 16 | $593 | $37 |
| Prednisone | 41 | $278 | $7 |
2020: 1 drug
| Promacta | 20 | $139,113 | $6,956 |
2019: 2 drugs
| Promacta | 16 | $114,906 | $7,182 |
| Venlafaxine Hcl Er | 14 | $430 | $31 |
2017: 1 drug
| Prednisone | 11 | $43 | $4 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Study of Tar200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle Invasive Bladder Cancer Mibc of the Bladder · 2024 | Their institution | $223,570 |
| PFIZER INC. · A Retrospective Chart Review of Realworld Treatment Outcomes in Patients With Locally Advanced Unresectable Or Metastatic Urothelial Cancer Based on Her2 Expression · 2024 | Their institution | $153,962 |
| Janssen Research & Development, LLC · A Study of Tar200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle Invasive Bladder Cancer Mibc of the Bladder · 2023 | Their institution | $90,082 |
| Janssen Research & Development, LLC · A Study of Tar200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle Invasive Bladder Cancer Mibc of the Bladder · 2025 | Their institution | $66,956 |
| PFIZER INC. · A Retrospective Chart Review of Realworld Treatment Outcomes in Patients With Locally Advanced Unresectable Or Metastatic Urothelial Cancer Based on Her2 Expression · 2025 | Their institution | $12,747 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407299530
- Licence
- CA A133860, WA MD60868159California A133860: Current · expires 2026-11-30Washington MD.MD.60868159: Active
- Trained
- University of California, San Diego School of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- WA 1407299530
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-08
- NPI last updated
- 2026-05-19
- NPI record certified
- 2026-05-19
This is when the NPI record was last certified, not a medical board exam.